Laurus Labs Delivers Strong 1QFY27 Operating Performance Driven by CDMO Expansion
Laurus Labs Ltd · Investor Presentation · 18 Sept 2026, 11:51 pm
Laurus Labs Delivers Strong 1QFY27 Operating Performance Driven by CDMO Expansion Laurus Labs reported strong 1QFY27 revenue of ₹2,026 Cr (up 29% YoY, 12% QoQ), led by robust CDMO growth. EBITDA rose 66% YoY to ₹644 Cr with margins expanding 700 bps YoY to 31.8%, driven by an improved mix and operating leverage. Net profit surged 126% YoY to ₹368 Cr. The company is executing a >₹3,000 Cr capex plan across FY27-FY28, allocating >85% toward growth in CDMO, fermentation, peptides, and advanced biologics. Management guides for sustained >30% EBITDA margins from FY27 onward.
Original exchange filing (PDF)
More announcements from Laurus Labs Ltd
- Please see annexed enclosure. · 18 Nov 2026
- Please see annexed enclosure. · 11 Nov 2026
- Please see annexed enclosure. · 03 Nov 2026
- Please see enclosed annexure. · 30 Oct 2026
- Please see enclosed annexure · 29 Oct 2026
- Please see enclosed annexure · 29 Oct 2026
- Please see enclosed annexure · 29 Oct 2026
- Appointment of Mr. Kundan Kumar Jha as Joint Company Secretary of the Company w.e.f. November 1, 2026 · 29 Oct 2026
